Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Aytu BioScience announces business strategy update and Q2 financial results

Aytu BioScience announces business strategy update and Q2 financial results

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

UI researchers uncover how cancer cells form tumors

UI researchers uncover how cancer cells form tumors

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Animal antibodies help identify diseased cells during immunohistology procedures

Animal antibodies help identify diseased cells during immunohistology procedures

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

MD Anderson signs collaborative research and development agreement with Enumeral

MD Anderson signs collaborative research and development agreement with Enumeral

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.